CytoReason, an Israeli startup that specializes in AI-enabled tools for the life sciences industry, has successfully secured $80 million in funding. The funding round saw participation from prominent investors including Pfizer, OurCrowd, NVIDIA, and Thermo Fisher Scientific.
The core focus of CytoReason’s computational model is to map and compare various treatments. By leveraging artificial intelligence, the startup offers data-driven and molecular-level insights to enhance the success rate of phase 2 clinical trials and optimize research and development processes.
The innovative model developed by CytoReason enables comprehensive analysis of datasets, literature, and cell states. This allows for a deep understanding of disease progression over time, the variation between patients, cell composition, and interactions, as well as the effects of different treatments on diseases.
The newly secured funds will be utilized by CytoReason to broaden the application of its computational models across different indications. Additionally, the company plans to expand its molecular and clinical data, enhancing its capabilities even further. CytoReason also intends to establish a new office in Cambridge, Massachusetts, later this year.
Mikael Dolsten, Pfizer’s Chief Scientific Officer and President of Worldwide Research, Development, and Medical, expressed his enthusiasm for the collaboration with CytoReason. He highlighted the significant potential of technologies like artificial intelligence in transforming the landscape of human health and drug development. Dolsten commended CytoReason’s cutting-edge immunology multiomics platform and the invaluable insights it provides for new pathways in drug development.
The recent funding success and expansion of CytoReason underline the growing importance of AI-enabled tools in revolutionizing the life sciences industry. With its innovative approach, the startup is poised to make significant contributions to the advancement of medical research and patient care.